linagliptin/metformin sandoz 2.5 mg/500 mg film-coated tablets
sandoz pharmaceuticals d.d. verovškova ulica 57, si-1000 ljubljana, slovenia - film-coated tablet - linagliptin 2.5 mg metformin hydrochloride 500 mg - drugs used in diabetes
linagliptin/metformin sandoz 2.5 mg/850 mg film-coated tablets
sandoz pharmaceuticals d.d. verovškova ulica 57, si-1000 ljubljana, slovenia - film-coated tablet - linagliptin 2.5 mg metformin hydrochloride 850 mg - drugs used in diabetes
linagliptin/metformin sandoz 2.5 mg/1000 mg film-coated tablets
sandoz pharmaceuticals d.d. verovškova ulica 57, si-1000 ljubljana, slovenia - film-coated tablet - linagliptin 2.5 mg metformin hydrochloride 1000 mg - drugs used in diabetes
linagliptin teva
teva israel ltd - linagliptin - film coated tablets - linagliptin 5 mg - linagliptin - as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. linagliptin teva® should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis, as it would not be effective in these settings.linagliptin teva® has not been studied in patients with a history of pancreatitis. it is unknown whether patients with a history of pancreatitis are at an increased risk for the development of pancreatitis while using linagliptin teva®.
trajenta duo 2.5 mg 500 mg
boehringer ingelheim israel ltd. - linagliptin; metformin hydrochloride - film coated tablets - metformin hydrochloride 500 mg; linagliptin 2.5 mg - metformin - metformin - as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both linagliptin and metformin is appropriate. trajenta-duo should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis, as it would not be effective in these settings. trajenta-duo has not been studied in patients with a history of pancreatitis. it is unknown whether patients with a history of pancreatitis are at an increased risk for the development of pancreatitis while using trajenta-duo.
trajenta duo 2.5 mg 850 mg
boehringer ingelheim israel ltd. - linagliptin; metformin hydrochloride - film coated tablets - metformin hydrochloride 850 mg; linagliptin 2.5 mg - metformin - metformin - as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both linagliptin and metformin is appropriate. trajenta-duo should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis, as it would not be effective in these settings. trajenta-duo has not been studied in patients with a history of pancreatitis. it is unknown whether patients with a history of pancreatitis are at an increased risk for the development of pancreatitis while using trajenta-duo.
trajenta duo 2.5 mg 850 mg
boehringer ingelheim israel ltd. - linagliptin; metformin hydrochloride - film coated tablets - metformin hydrochloride 850 mg; linagliptin 2.5 mg - metformin - as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both linagliptin and metformin is appropriate. trajenta-duo should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis, as it would not be effective in these settings. trajenta-duo has not been studied in patients with a history of pancreatitis. it is unknown whether patients with a history of pancreatitis are at an increased risk for the development of pancreatitis while using trajenta-duo.
glyxambi 10 mg/5 mg empagliflozin/linagliptin 10mg/5mg film coated tablet blister pack
boehringer ingelheim pty ltd - empagliflozin, quantity: 10 mg; linagliptin, quantity: 5 mg - tablet, film coated - excipient ingredients: iron oxide yellow; macrogol 6000; hypromellose; crospovidone; maize starch; titanium dioxide; mannitol; purified talc; pregelatinised maize starch; copovidone; magnesium stearate - glyxambi tablets are indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus when treatment with both empagliflozin and linagliptin is appropriate (see sections 4.2 dose and method of administration and 5.1 pharmacodynamic properties ? clinical trials).
glyxambi 10 mg5 mg
boehringer ingelheim israel ltd. - empagliflozin; linagliptin - film coated tablets - linagliptin 5 mg; empagliflozin 10 mg - linagliptin and empagliflozin - glyxambi tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both empagliflozin and linagliptin is appropriate. limitations of useglyxambi is not recommended for patients with type 1 diabetes or for the treatment of diabetic ketoacidosis.glyxambi has not been studied in patients with a history of pancreatitis. it is unknown whether patients with a history of pancreatitis are at an increased risk for the development of pancreatitis while using glyxambi.
glyxambi 25 mg5 mg
boehringer ingelheim israel ltd. - empagliflozin; linagliptin - film coated tablets - linagliptin 5 mg; empagliflozin 25 mg - linagliptin and empagliflozin - glyxambi tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both empagliflozin and linagliptin is appropriate. limitations of useglyxambi is not recommended for patients with type 1 diabetes or for the treatment of diabetic ketoacidosis.glyxambi has not been studied in patients with a history of pancreatitis. it is unknown whether patients with a history of pancreatitis are at an increased risk for the development of pancreatitis while using glyxambi.